« Coartem et paludisme » - Novartis lance un programme d'éducation international

April 24, 2003 04:15 ET | Source: Novartis Pharma AG Novartis Pharma AG

Des photographies illustrant Coartem sont disponibles dans un Virtual Media Kit sur le site Internet de Novartis dans la section "media releases":

http://dominoext.novartis.com/NC/NCPRRE01.nsf

Please see full press release under the following link

Attachments

Media Release...

Recommended Reading

October 07, 2026 11:45 ET | Source: Novartis Pharma AG

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible...
Read More
October 07, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and...
Read More